e-learning
resources
ERJ
2002
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler(R)
Johnell O., Pauwels R., Lofdahl C-G., Laitinen L.A., Postma D.S., Pride N.B., Ohlsson S.V.
Source:
Eur Respir J 2002; 19: 1058-1063
Journal Issue:
June
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Johnell O., Pauwels R., Lofdahl C-G., Laitinen L.A., Postma D.S., Pride N.B., Ohlsson S.V.. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler(R). Eur Respir J 2002; 19: 1058-1063
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
Loss of bone mineral density in patients with chronic obstructive pulmonary disease
Source: Annual Congress 2007 - Primary care management of COPD
Year: 2007
Current status of research on osteoporosis in COPD: a systematic review
Source: Eur Respir J 2009; 34: 209-218
Year: 2009
Bone turnover markers, bone mineral density and body composition in Tunisian patients with chronic obstructive pulmonary disease
Source: Virtual Congress 2021 – Management of chronic cough and obstructive diseases
Year: 2021
To study the severity of lung hyperinflation and bone mineral density in patients with chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2013 –COPD mechanisms
Year: 2013
Bone mineral density changes in male patients with chronic obstructive pulmonary disease: clinical and biochemical variables in correlation with glucocorticoids use
Source: Annual Congress 2009 - Healthcare and treatment of COPD
Year: 2009
Relationship between annual change of bone mineral density, emphysema and pulmonary function in patients with COPD
Source: International Congress 2015 – COPD: notable points
Year: 2015
The efficacy of formoterol in patients with chronic obstructive pulmonary disease (COPD) is not influenced by concomitant corticosteroid use
Source: Eur Respir J 2001; 18: Suppl. 33, 515s
Year: 2001
Clinical severity of chronic obstructive pulmonary disease is associated with bone mineral density
Source: International Congress 2015 – Clinical assessment and monitoring of asthma and COPD
Year: 2015
Osteoporosis risk assessment in elderly male patients with COPD who use inhaled corticosteroids
Source: Annual Congress 2006 - COPD therapy
Year: 2006
Osteoporosis in chronic obstructive pulmonary disease
Source: Eur Respir J 2003; 22: 64S-75S
Year: 2003
Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter?
Source: Eur Respir J 2003; 21: 260-266
Year: 2003
What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations?
Source: Eur Respir J 2002; 19: 928-935
Year: 2002
Study of bone mineral density, hemogram and their correlations in patients with chronic obstructive pulmonary disease
Source: International Congress 2014 – Respiratory disease within hospital-based populations
Year: 2014
Bronchodilatory effects of formoterol in patients with chronic obstructive pulmonary disease (COPD) are not influenced by concomitant corticosteroid use
Source: Eur Respir J 2001; 18: Suppl. 33, 514s
Year: 2001
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease
Source: Eur Respir J 2003; 21: 74-81
Year: 2003
A comparison of bone mineral density in elderly patients with COPD and bronchial asthma
Source: Annual Congress 2007 - COPD and comorbidity
Year: 2007
Alveolar absorption and systemic bioactivity of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease
Source: Eur Respir J 2004; 24: Suppl. 48, 13s
Year: 2004
Undertreatment of loss of bone mineral density in patients with COPD who were referred for pulmonary rehabilitation
Source: Eur Respir J 2006; 28: Suppl. 50, 71s
Year: 2006
A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease
Source: Eur Respir J 2002; 19: 217-224
Year: 2002
Corticosteroid sensitivity in patients with chronic obstructive pulmonary disease is restored by theophylline
Source: Annual Congress 2005 - Therapeutic options for COPD: present and future
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept